Rita Carvalho, Thomas Zander, Vincenzo Mitchell Barroso, Ahmet Bekisoglu, Norman Zerbe, Sebastian Klein, Reinhard Büttner, Alexander Quaas, Yuri Tolkach
{"title":"AI-based tumor-stroma ratio quantification algorithm: comprehensive evaluation of prognostic role in primary colorectal cancer.","authors":"Rita Carvalho, Thomas Zander, Vincenzo Mitchell Barroso, Ahmet Bekisoglu, Norman Zerbe, Sebastian Klein, Reinhard Büttner, Alexander Quaas, Yuri Tolkach","doi":"10.1007/s00428-025-04048-y","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor-stroma ratio (TSR quantification in primary colorectal cancer is an important prognostic parameter, with stroma-rich tumors considered to have an unfavorable prognosis. Earlier studies involved relevant region selection and TSR quantification by human analysts, who are prone to interobserver variability. The aim of the current study was to develop a fully automated, quantitative algorithm for TSR analysis based on precise segmentation of H&E-stained histological tissue sections. The TSR quantification algorithm was developed based on the segmentation backbone, allowing accurate pixel-wise mapping of all relevant tissue classes (n = 12), including tumor cells, tumoral stroma, necrosis, and mucin. Three well-characterized cohorts of patients with stage I-IV primary operable colorectal cancer and available digital H&E histological slides were included (n = 548, n = 147, and n = 622, respectively). Three sizes of area for TSR analysis were tested (1.0, 1.5, and 2.0 mm). The maximal TSR value per case was used for prognostic analysis involving different clinical endpoints. Regional heterogeneity of TSR was high in most tumors, with the algorithm effectively finding the most relevant region for analysis. Maximal case-level TSR values depended on the size of the area for analysis, which also significantly influences the prognostic performance of the TSR and must be a matter of standardization. In Cox analysis, an analytical size of 1 mm allowed the best performance, with an independent prognostic role retained in the context of other pathological variables for progression-free survival, cancer-specific survival, and overall survival endpoints. A powerful, fully automated, fully quantitative, objective tool for TSR assessment in primary colorectal cancer was developed and validated to have independent prognostic value. Standardization of TSR quantification is important given that analytical parameters can substantially influence the prognostic performance.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04048-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Tumor-stroma ratio (TSR quantification in primary colorectal cancer is an important prognostic parameter, with stroma-rich tumors considered to have an unfavorable prognosis. Earlier studies involved relevant region selection and TSR quantification by human analysts, who are prone to interobserver variability. The aim of the current study was to develop a fully automated, quantitative algorithm for TSR analysis based on precise segmentation of H&E-stained histological tissue sections. The TSR quantification algorithm was developed based on the segmentation backbone, allowing accurate pixel-wise mapping of all relevant tissue classes (n = 12), including tumor cells, tumoral stroma, necrosis, and mucin. Three well-characterized cohorts of patients with stage I-IV primary operable colorectal cancer and available digital H&E histological slides were included (n = 548, n = 147, and n = 622, respectively). Three sizes of area for TSR analysis were tested (1.0, 1.5, and 2.0 mm). The maximal TSR value per case was used for prognostic analysis involving different clinical endpoints. Regional heterogeneity of TSR was high in most tumors, with the algorithm effectively finding the most relevant region for analysis. Maximal case-level TSR values depended on the size of the area for analysis, which also significantly influences the prognostic performance of the TSR and must be a matter of standardization. In Cox analysis, an analytical size of 1 mm allowed the best performance, with an independent prognostic role retained in the context of other pathological variables for progression-free survival, cancer-specific survival, and overall survival endpoints. A powerful, fully automated, fully quantitative, objective tool for TSR assessment in primary colorectal cancer was developed and validated to have independent prognostic value. Standardization of TSR quantification is important given that analytical parameters can substantially influence the prognostic performance.
原发性结直肠癌的肿瘤-基质比(TSR)定量是一个重要的预后参数,富含基质的肿瘤被认为预后不良。早期的研究涉及相关区域的选择和由人类分析师进行 TSR 定量,而人类分析师容易出现观察者之间的差异。本研究的目的是在精确分割 H&E 染色组织切片的基础上,开发一种全自动 TSR 定量分析算法。TSR 定量算法是在分割骨架的基础上开发的,可对所有相关组织类别(n = 12)进行精确的像素映射,包括肿瘤细胞、肿瘤基质、坏死和粘蛋白。三组特征明确的 I-IV 期原发性可手术结直肠癌患者和可用的数字 H&E 组织学切片(分别为 548 张、147 张和 622 张)被纳入其中。测试了用于 TSR 分析的三种面积大小(1.0、1.5 和 2.0 毫米)。每个病例的最大 TSR 值用于涉及不同临床终点的预后分析。在大多数肿瘤中,TSR 的区域异质性很高,算法能有效找到最相关的区域进行分析。病例级 TSR 的最大值取决于分析区域的大小,这也极大地影响了 TSR 的预后效果,必须加以标准化。在 Cox 分析中,1 毫米的分析面积可达到最佳效果,在无进展生存期、癌症特异性生存期和总生存期终点的其他病理变量背景下,仍具有独立的预后作用。针对原发性结直肠癌的 TSR 评估开发了一种功能强大、全自动、完全定量的客观工具,并验证了其具有独立的预后价值。由于分析参数会对预后效果产生重大影响,因此 TSR 定量的标准化非常重要。
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.